Ketorolac (Toradol) Dosing
For adults, use 30 mg IV every 6 hours (maximum 120 mg/day) for patients <65 years, or 15 mg IV every 6 hours (maximum 60 mg/day) for patients ≥65 years, renally impaired, or <50 kg, with a strict 5-day maximum duration including any oral continuation. For children, use 0.5 mg/kg IV (maximum 30 mg single dose) followed by 0.15-0.2 mg/kg every 6 hours (maximum 10 mg per dose) for a maximum of 48 hours 1, 2.
Adult Dosing
Multiple-Dose Regimen (Standard)
Patients <65 years: 30 mg IV/IM every 6 hours
- Maximum daily dose: 120 mg
- Maximum duration: 5 days total (IV/IM + oral combined) 1
Patients ≥65 years, renally impaired, or <50 kg (110 lbs): 15 mg IV/IM every 6 hours
- Maximum daily dose: 60 mg
- Maximum duration: 5 days total 1
Single-Dose Regimen
- IV route: 30 mg (<65 years) or 15 mg (≥65 years/high-risk)
- IM route: 60 mg (<65 years) or 30 mg (≥65 years/high-risk)
- Limited to one-time administration only 1
Administration Details
- IV bolus must be given over ≥15 seconds 1
- Onset of analgesia: ~30 minutes
- Peak effect: 1-2 hours
- Duration: 4-6 hours 1
Pediatric Dosing
Ketorolac is NOT FDA-approved for pediatric use 1, but evidence-based guidelines support its use in children >1 year for postoperative pain:
Intraoperative/Initial Dose
- 0.5-1 mg/kg IV (maximum 30 mg single dose) 2
Postoperative Maintenance
- 0.15-0.2 mg/kg IV every 6 hours (maximum 10 mg per dose)
- Maximum duration: 48 hours 2
- Maximum daily dose: 90 mg 3
Age-Specific Considerations
- Not recommended for infants <1 year 3
- Pharmacokinetic studies show children 1-16 years have similar elimination half-lives to adults but increased volume of distribution, justifying weight-based dosing 4, 5
- A 0.5 mg/kg dose every 6 hours maintains therapeutic concentrations (>0.37 mg/L) in children 9 months to 16 years 4
Critical Safety Warnings
Duration Limits
The 5-day maximum for adults (combined IV/IM/oral) and 48-hour maximum for children are absolute limits to minimize serious adverse events 1, 2. Even short-term use carries GI bleeding risk 1.
High-Risk Populations Requiring Dose Reduction (15 mg in adults)
- Age ≥65 years
- Renal impairment
- Weight <50 kg (110 lbs)
- History of peptic ulcer disease (contraindicated if active) 1
Contraindications
- Active peptic ulcer disease or GI bleeding history
- Coagulation disorders
- Concurrent anticoagulant therapy (relative contraindication—use "extremely cautiously") 1
- Advanced renal impairment
- Perioperative pain in CABG surgery 1
Common Pitfalls
- Do not mix in syringe with morphine, meperidine, promethazine, or hydroxyzine—causes precipitation 1
- Do not increase dose or frequency for breakthrough pain; instead add low-dose opioids 1
- Correct hypovolemia before administration to prevent renal complications 1
- GI bleeding can occur without warning symptoms—only 1 in 5 patients with serious GI events are symptomatic 1
Clinical Context
Recent evidence demonstrates ketorolac's effectiveness as an opioid-sparing agent. In pediatric studies, ketorolac showed superior pain reduction compared to opioids with a favorable safety profile 6. A 2024 study in pediatric headache patients ≥60 kg found that 15 mg was non-inferior to 30 mg, suggesting a ceiling effect at lower doses 7. However, the FDA label and established guidelines remain the authoritative dosing standards 1, 2.
For postoperative pain, ketorolac demonstrates efficacy equivalent to morphine with significantly fewer adverse effects (no respiratory depression, nausea, urinary retention, or sedation) 3. When combined with opioids, it provides synergistic analgesia allowing opioid dose reduction 3.